NRX Pharmaceuticals (NRXP) Total Current Liabilities (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Total Current Liabilities data on file, last reported at $25.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 23.13% year-over-year to $25.2 million in Q1 2026; TTM through Mar 2026 was $25.2 million, a 23.13% decrease from a year earlier, with the FY2025 full-year figure at $28.6 million, up 30.71% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $25.2 million, down from $28.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for NRXP reached as high as $40.6 million in Q3 2025 and fell as low as $15.6 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $25.7 million across 5 years, with a median of $22.3 million in 2023.
• Across the five-year window, Total Current Liabilities soared 99.98% in 2025 and slipped 23.13% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $15.6 million in 2022, then increased by 22.22% to $19.0 million in 2023, then gained by 14.78% to $21.9 million in 2024, then surged by 30.71% to $28.6 million in 2025, then dropped by 11.9% to $25.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $25.2 million in Q1 2026, $28.6 million in Q4 2025, and $40.6 million in Q3 2025.